At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 486 enrolled
Drug / intervention
FX006 +2 moredrug
Likely dose
FX006 5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Randomized, Single-Dose Study to Assess the Safety and Efficacy of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee
In Brief
A Phase 3 clinical trial evaluating FX006, Placebo, and 1 other intervention for Osteoarthritis of the Knee. Completed, enrolled 486 participants across 38 sites in 8 countries.
Detailed Summary
The purpose of this study was to assess the safety and efficacy of FX006 for the treatment of pain in patients with osteoarthritis of the knee.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis of the Knee
CountriesAustralia, Canada, Denmark, Estonia, Hong Kong, Lithuania, Romania, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJan 2015
First PostedFeb 2015
Primary CompletionJan 2016
TodayJul 2026
First PostedFeb 6, 2015
Enrollment StartJan 1, 2015
Primary CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 11.4 years ago
Interventions
FX006drug
Single 5 mL IA injection
Placebodrug
Single 5 mL IA injection
TCA IR 40drug
Single 1 mL IA injection